Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

Hahnen, Eric; Lederer, Bianca; Hauke, Jan; Loibl, Sibylle; Kröber, Sandra; Schneeweiß, Andreas; Denkert, Carsten; A. Fasching, Peter; Blohmer, Jens‐Uwe; Jackisch, Christian; Paepke, Stefan; Gerber, Bernd; Kümmel, Sherko; Schem, Christian; Neidhardt, Guido; Huober, Jens; Rhiem, Kerstin; Dan Costa, Serban; Altmüller, Janine; Hanusch, Claus; Thiele, Hölger; Müller, Volkmar; Nürnberg, Peter; Karn, Thomas; Nekljudova, Valentina; Untch, Michael; von Minckwitz, Gϋnter; K. Schmutzler, Rita

doi:10.1001/jamaoncol.2017.1007

Public

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

Published in JAMA Oncology • Jul 17, 2017

Authors:

Eric Hahnen

Bianca Lederer

Jan Hauke

Abstract

IMPORTANCE: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germli...

Subject

Medicine

Carboplatin

Breast cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!